Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease

Progress in Neurobiology

Volumn 151, Issue , 2017, Pages 4-34

  Ismaili, Lhassane ^a   Refouvelet, Bernard ^a   Benchekroun, Mohamed ^a   Brogi, Simone ^b   Brindisi, Margherita ^b   Gemma, Sandra ^b   Campiani, Giuseppe ^b   Filipic, Slavica ^c   Agbaba, Danica ^c   Esteban, Gerard ^d   Unzeta, Mercedes ^d   Nikolic, Katarina ^c   Butini, Stefania ^b   Marco Contelles, José ^e  

^a University Hospital of Besançon   (France)

^b UNIVERSITY OF SIENA   (Italy)

^c UNIVERSITY OF BELGRADE   (Serbia)

^d INSTITUT DE NEUROCIÈNCIES   (Spain)

^e INSTITUTO DE QUÍMICA ORGÁNICA GENERAL   (Spain)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Beta secretase; Butyrylcholinesterase; Cholinesterases; Histamine receptor; Monoamine oxidases; Multi target directed ligand; Nitric oxide; Reactive oxygen species; Serotonin receptors; Amyloid

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); AMYLOID BETA PROTEIN; BETA SECRETASE; BETA SECRETASE INHIBITOR; CHOLINESTERASE INHIBITOR; DONEPEZIL; MONOAMINE OXIDASE INHIBITOR; NITRIC OXIDE; SEROTONIN RECEPTOR; SIGMA 1 OPIATE RECEPTOR; TACRINE DERIVATIVE; TAU PROTEIN; INDAN DERIVATIVE; LIGAND; PIPERIDINE DERIVATIVE; TACRINE;

ALZHEIMER DISEASE; ANTICHOLINERGIC EFFECT; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CHELATION; DRUG EFFICACY; DRUG MECHANISM; MOLECULAR DYNAMICS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; ANIMAL; CHEMISTRY; HUMAN;

ALZHEIMER DISEASE; ANIMALS; CHOLINESTERASE INHIBITORS; HUMANS; INDANS; LIGANDS; PIPERIDINES; TACRINE;

EID: 84956685110     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2015.12.003     Document Type: Review

References (237)

1. Abuhamdah, S., Habash, M., Taha, M.O., Elaborate ligand-based modeling coupled with QSAR analysis and in silico screening reveal new potent acetylcholinesterase inhibitors. J. Comput. Aided Mol. Des. 27 (2013), 1075–1092.
2. Adayev, T., Wegiel, J., Hwang, Y.W., Harmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A). Arch. Biochem. Biophys. 507 (2011), 212–218.
3. Alvarez, A., Opazo, C., Alarcon, R., Garrido, J., Inestrosa, N.C., Acetylcholinesterase promotes the aggregation of amyloid-beta-peptide fragments by forming a complex with the growing fibrils. J. Mol. Biol. 272 (1997), 348–361.
4. Anand, P., Singh, B., Singh, N., A review on coumarins as acetylcholinesterase inhibitors for Alzheimer's disease. Bioorg. Med. Chem. 20 (2012), 1175–1180.
5. Andersson, C.D., Forsgren, N., Akfur, C., Allgardsson, A., Berg, L., Engdahl, C., Qian, W., Ekstrom, F., Linusson, A., Divergent structure–activity relationships of structurally similar acetylcholinesterase inhibitors. J. Med. Chem. 56 (2013), 7615–7624.
6. Arce, M.P., Rodriguez-Franco, M.I., Gonzalez-Munoz, G.C., Perez, C., Lopez, B., Villarroya, M., Lopez, M.G., Garcia, A.G., Conde, S., Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease. J. Med. Chem. 52 (2009), 7249–7257.
7. Asadipour, A., Alipour, M., Jafari, M., Khoobi, M., Emami, S., Nadri, H., Sakhteman, A., Moradi, A., Sheibani, V., Homayouni Moghadam, F., Shafiee, A., Foroumadi, A., Novel coumarin-3-carboxamides bearing N-benzylpiperidine moiety as potent acetylcholinesterase inhibitors. Eur. J. Med. Chem. 70 (2013), 623–630.
8. Avramovich-Tirosh, Y., Amit, T., Bar-Am, O., Zheng, H., Fridkin, M., Youdim, M.B., Therapeutic targets and potential of the novel brain-permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease. J. Neurochem. 100 (2007), 490–502.
9. Bag, S., Tulsan, R., Sood, A., Datta, S., Torok, M., Pharmacophore modeling, virtual and in vitro screening for acetylcholinesterase inhibitors and their effects on amyloid-beta self-assembly. Curr. Comput. Aided Drug Des. 9 (2013), 2–14.
10. Bai, F., Xu, Y., Chen, J., Liu, Q., Gu, J., Wang, X., Ma, J., Li, H., Onuchic, J.N., Jiang, H., Free energy landscape for the binding process of Huperzine A to acetylcholinesterase. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 4273–4278.
11. Bajda, M., Guzior, N., Ignasik, M., Malawska, B., Multi-target-directed ligands in Alzheimer's disease treatment. Curr. Med. Chem. 18 (2011), 4949–4975.
12. Bajda, M., Wieckowska, A., Hebda, M., Guzior, N., Sotriffer, C.A., Malawska, B., Structure-based search for new inhibitors of cholinesterases. Int. J. Mol. Sci. 14 (2013), 5608–5632.
13. Bartolini, M., Bertucci, C., Cavrini, V., Andrisano, V., β-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochem. Pharmacol. 65 (2003), 407–416.
14. Bautista-Aguilera, O.M., Esteban, G., Bolea, I., Nikolic, K., Agbaba, D., Moraleda, I., Iriepa, I., Samadi, A., Soriano, E., Unzeta, M., Marco-Contelles, J., Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil-indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease. Eur. J. Med. Chem. 75 (2014), 82–95.
15. Bautista-Aguilera, O.M., Esteban, G., Chioua, M., Nikolic, K., Agbaba, D., Moraleda, I., Iriepa, I., Soriano, E., Samadi, A., Unzeta, M., Marco-Contelles, J., Multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease: design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybrids. Drug Des. Devel. Ther. 8 (2014), 1893–1910.
16. Bautista-Aguilera, O.M., Samadi, A., Chioua, M., Nikolic, K., Filipic, S., Agbaba, D., Soriano, E., de Andres, L., Rodriguez-Franco, M.I., Alcaro, S., Ramsay, R.R., Ortuso, F., Yanez, M., Marco-Contelles, J., N-methyl-N-((1-methyl-5-(3-(1-(2-methylbenzyl)piperidin-4-yl)propoxy)-1H-indol-2-yl)methyl)prop-2-yn-1-amine, a new cholinesterase and monoamine oxidase dual inhibitor. J. Med. Chem., 2014.
17. Benchekroun, M., Bartolini, M., Egea, J., Romero, A., Soriano, E., Pudlo, M., Luzet, V., Andrisano, V., Jimeno, M.L., Lopez, M.G., Wehle, S., Gharbi, T., Refouvelet, B., de Andres, L., Herrera-Arozamena, C., Monti, B., Bolognesi, M.L., Rodriguez-Franco, M.I., Decker, M., Marco-Contelles, J., Ismaili, L., Novel tacrine-grafted Ugi adducts as multipotent anti-Alzheimer drugs: a synthetic renewal in tacrine-ferulic acid hybrids. ChemMedChem 10 (2015), 523–539.
18. Benchekroun, M., Ismaili, L., Pudlo, M., Luzet, V., Gharbi, T., Refouvelet, B., Marco-Contelles, J., Donepezil-ferulic acid hybrids as anti-Alzheimer drugs. Future Med. Chem. 7 (2015), 15–21.
19. Benilova, I., Karran, E., De Strooper, B., The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes. Nat. Neurosci. 15 (2012), 349–357.
20. Bennion, B.J., Essiz, S.G., Lau, E.Y., Fattebert, J.L., Emigh, A., Lightstone, F.C., A wrench in the works of human acetylcholinesterase: soman induced conformational changes revealed by molecular dynamics simulations. PLOS ONE, 10, 2015, e0121092.
21. Benzie, I.F., Strain, J.J., Ferric reducing/antioxidant power assay: direct measure of total antioxidant activity of biological fluids and modified version for simultaneous measurement of total antioxidant power and ascorbic acid concentration. Methods Enzymol. 299 (1999), 15–27.
22. Bergeron, R., de Montigny, C., Debonnel, G., Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via sigma receptors. J. Neurosci. 16 (1996), 1193–1202.
23. Bermudez-Lugo, J.A., Rosales-Hernandez, M.C., Deeb, O., Trujillo-Ferrara, J., Correa-Basurto, J., In silico methods to assist drug developers in acetylcholinesterase inhibitor design. Curr. Med. Chem. 18 (2011), 1122–1136.
24. Besnard, J., Ruda, G.F., Setola, V., Abecassis, K., Rodriguiz, R.M., Huang, X.P., Norval, S., Sassano, M.F., Shin, A.I., Webster, L.A., Simeons, F.R., Stojanovski, L., Prat, A., Seidah, N.G., Constam, D.B., Bickerton, G.R., Read, K.D., Wetsel, W.C., Gilbert, I.H., Roth, B.L., Hopkins, A.L., Automated design of ligands to polypharmacological profiles. Nature 492 (2012), 215–220.
25. Bolea, I., Gella, A., Monjas, L., Perez, C., Rodriguez-Franco, M.I., Marco-Contelles, J., Samadi, A., Unzeta, M., Multipotent, permeable drug ASS234 inhibits Abeta aggregation, possesses antioxidant properties and protects from Abeta-induced apoptosis in vitro. Curr. Alzheimer Res. 10 (2013), 797–808.
26. Bolea, I., Juarez-Jimenez, J., de Los Rios, C., Chioua, M., Pouplana, R., Luque, F.J., Unzeta, M., Marco-Contelles, J., Samadi, A., Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease. J. Med. Chem. 54 (2011), 8251–8270.
27. Bolognesi, M.L., Cavalli, A., Valgimigli, L., Bartolini, M., Rosini, M., Andrisano, V., Recanatini, M., Melchiorre, C., Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease. J. Med. Chem. 50 (2007), 6446–6449.
28. Brogi, S., Butini, S., Maramai, S., Colombo, R., Verga, L., Lanni, C., De Lorenzi, E., Lamponi, S., Andreassi, M., Bartolini, M., Andrisano, V., Novellino, E., Campiani, G., Brindisi, M., Gemma, S., Disease-modifying anti-Alzheimer's drugs: inhibitors of human cholinesterases interfering with beta-amyloid aggregation. CNS Neurosci. Ther. 20 (2014), 624–632.
29. Brogi, S., Corelli, F., Di Marzo, V., Ligresti, A., Mugnaini, C., Pasquini, S., Tafi, A., Three-dimensional quantitative structure–selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2. Eur. J. Med. Chem. 46 (2011), 547–555.
30. Brogi, S., Kladi, M., Vagias, C., Papazafiri, P., Roussis, V., Tafi, A., Pharmacophore modeling for qualitative prediction of antiestrogenic activity. J. Chem. Inf. Model. 49 (2009), 2489–2497.
31. Brogi, S., Papazafiri, P., Roussis, V., Tafi, A., 3D-QSAR using pharmacophore-based alignment and virtual screening for discovery of novel MCF-7 cell line inhibitors. Eur. J. Med. Chem. 67 (2013), 344–351.
32. Bui, J.M., Henchman, R.H., McCammon, J.A., The dynamics of ligand barrier crossing inside the acetylcholinesterase gorge. Biophys. J. 85 (2003), 2267–2272.
33. Bui, J.M., Tai, K., McCammon, J.A., Acetylcholinesterase: enhanced fluctuations and alternative routes to the active site in the complex with fasciculin-2. J. Am. Chem. Soc. 126 (2004), 7198–7205.
34. Butini, S., Brindisi, M., Brogi, S., Maramai, S., Guarino, E., Panico, A., Saxena, A., Chauhan, V., Colombo, R., Verga, L., De Lorenzi, E., Bartolini, M., Andrisano, V., Novellino, E., Campiani, G., Gemma, S., Multifunctional cholinesterase and amyloid Beta fibrillization modulators. Synthesis and biological investigation. ACS Med. Chem. Lett. 4 (2013), 1178–1182.
35. Butini, S., Brogi, S., Novellino, E., Campiani, G., Ghosh, A.K., Brindisi, M., Gemma, S., The structural evolution of beta-secretase inhibitors: a focus on the development of small-molecule inhibitors. Curr. Top. Med. Chem. 13 (2013), 1787–1807.
36. Butini, S., Campiani, G., Borriello, M., Gemma, S., Panico, A., Persico, M., Catalanotti, B., Ros, S., Brindisi, M., Agnusdei, M., Fiorini, I., Nacci, V., Novellino, E., Belinskaya, T., Saxena, A., Fattorusso, C., Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely potent inhibitors. J. Med. Chem. 51 (2008), 3154–3170.
37. Butini, S., Gabellieri, E., Brindisi, M., Giovani, S., Maramai, S., Kshirsagar, G., Guarino, E., Brogi, S., La Pietra, V., Giustiniano, M., Marinelli, L., Novellino, E., Campiani, G., Cappelli, A., Gemma, S., A stereoselective approach to peptidomimetic BACE1 inhibitors. Eur. J. Med. Chem. 70C (2013), 233–247.
38. Butini, S., Guarino, E., Campiani, G., Brindisi, M., Coccone, S.S., Fiorini, I., Novellino, E., Belinskaya, T., Saxena, A., Gemma, S., Tacrine based human cholinesterase inhibitors: synthesis of peptidic-tethered derivatives and their effect on potency and selectivity. Bioorg. Med. Chem. Lett. 18 (2008), 5213–5216.
39. Campiani, G., Fattorusso, C., Butini, S., Gaeta, A., Agnusdei, M., Gemma, S., Persico, M., Catalanotti, B., Savini, L., Nacci, V., Novellino, E., Holloway, H.W., Greig, N.H., Belinskaya, T., Fedorko, J.M., Saxena, A., Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE), Rational design of novel, selective, and highly potent BuChE inhibitors. J. Med. Chem. 48 (2005), 1919–1929.
40. Camps, P., Cusack, B., Mallender, W.D., El Achab, R.E., Morral, J., Munoz-Torrero, D., Rosenberry, T.L., Huprine X is a novel high-affinity inhibitor of acetylcholinesterase that is of interest for treatment of Alzheimer's disease. Mol. Pharmacol. 57 (2000), 409–417.
41. Cappelli, A., Manini, M., Valenti, S., Castriconi, F., Giuliani, G., Anzini, M., Brogi, S., Butini, S., Gemma, S., Campiani, G., Giorgi, G., Mennuni, L., Lanza, M., Giordani, A., Caselli, G., Letari, O., Makovec, F., Synthesis and structure–activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds. Eur. J. Med. Chem. 63 (2013), 85–94.
42. Carlier, P.R., Chow, E.S., Han, Y., Liu, J., El Yazal, J., Pang, Y.P., Heterodimeric tacrine-based acetylcholinesterase inhibitors: investigating ligand-peripheral site interactions. J. Med. Chem. 42 (1999), 4225–4231.
43. Carlier, P.R., Han, Y.F., Chow, E.S., Li, C.P., Wang, H., Lieu, T.X., Wong, H.S., Pang, Y.P., Evaluation of short-tether bis-THA AChE inhibitors. A further test of the dual binding site hypothesis. Bioorg. Med. Chem. 7 (1999), 351–357.
44. Carreiras, M.C., Mendes, E., Perry, M.J., Francisco, A.P., Marco-Contelles, J., The multifactorial nature of Alzheimer's disease for developing potential therapeutics. Curr. Top. Med. Chem. 13 (2013), 1745–1770.
45. Castelli, M.P., Casu, A., Casti, P., Lobina, C., Carai, M.A., Colombo, G., Solinas, M., Giunta, D., Mugnaini, C., Pasquini, S., Tafi, A., Brogi, S., Gessa, G.L., Corelli, F., Characterization of COR627 and COR628, two novel positive allosteric modulators of the GABA(B) receptor. J. Pharmacol. Exp. Ther. 340 (2012), 529–538.
46. Catto, M., Pisani, L., Leonetti, F., Nicolotti, O., Pesce, P., Stefanachi, A., Cellamare, S., Carotti, A., Design, synthesis and biological evaluation of coumarin alkylamines as potent and selective dual binding site inhibitors of acetylcholinesterase. Bioorg. Med. Chem. 21 (2013), 146–152.
47. Chao, X., He, X., Yang, Y., Zhou, X., Jin, M., Liu, S., Cheng, Z., Liu, P., Wang, Y., Yu, J., Tan, Y., Huang, Y., Qin, J., Rapposelli, S., Pi, R., Design, synthesis and pharmacological evaluation of novel tacrine-caffeic acid hybrids as multi-targeted compounds against Alzheimer's disease. Bioorg. Med. Chem. Lett. 22 (2012), 6498–6502.
48. Chaudhaery, S.S., Roy, K.K., Shakya, N., Saxena, G., Sammi, S.R., Nazir, A., Nath, C., Saxena, A.K., Novel carbamates as orally active acetylcholinesterase inhibitors found to improve scopolamine-induced cognition impairment: pharmacophore-based virtual screening, synthesis, and pharmacology. J. Med. Chem. 53 (2010), 6490–6505.
49. Chen, H.S., Pellegrini, J.W., Aggarwal, S.K., Lei, S.Z., Warach, S., Jensen, F.E., Lipton, S.A., Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J. Neurosci. 12 (1992), 4427–4436.
50. Chen, Y., Fang, L., Peng, S., Liao, H., Lehmann, J., Zhang, Y., Discovery of a novel acetylcholinesterase inhibitor by structure-based virtual screening techniques. Bioorg. Med. Chem. Lett. 22 (2012), 3181–3187.
51. Chen, Y., Sun, J., Fang, L., Liu, M., Peng, S., Liao, H., Lehmann, J., Zhang, Y., Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl- and butyrylcholinesterase inhibitors. J. Med. Chem. 55 (2012), 4309–4321.
52. Chen, Y., Sun, J., Peng, S., Liao, H., Zhang, Y., Lehmann, J., Tacrine-flurbiprofen hybrids as multifunctional drug candidates for the treatment of Alzheimer's disease. Arch. Pharm. (Weinheim) 346 (2013), 865–871.
53. Cherkasov, A., Muratov, E.N., Fourches, D., Varnek, A., Baskin, I.I., Cronin, M., Dearden, J., Gramatica, P., Martin, Y.C., Todeschini, R., Consonni, V., Kuz'min, V.E., Cramer, R., Benigni, R., Yang, C., Rathman, J., Terfloth, L., Gasteiger, J., Richard, A., Tropsha, A., QSAR modeling: where have you been? Where are you going to?. J. Med. Chem. 57 (2014), 4977–5010.
54. Cheung, J., Rudolph, M.J., Burshteyn, F., Cassidy, M.S., Gary, E.N., Love, J., Franklin, M.C., Height, J.J., Structures of human acetylcholinesterase in complex with pharmacologically important ligands. J. Med. Chem. 55 (2012), 10282–10286.
55. Clark, J.K., Cowley, P., Muir, A.W., Palin, R., Pow, E., Prosser, A.B., Taylor, R., Zhang, M.Q., Quaternary salts of E2020 analogues as acetylcholinesterase inhibitors for the reversal of neuromuscular block. Bioorg. Med. Chem. Lett. 12 (2002), 2565–2568.
56. Contreras, J.M., Parrot, I., Sippl, W., Rival, Y.M., Wermuth, C.G., Design, synthesis, and structure–activity relationships of a series of 3-[2-(1-benzylpiperidin-4-yl)ethylamino]pyridazine derivatives as acetylcholinesterase inhibitors. J. Med. Chem. 44 (2001), 2707–2718.
57. Contreras, J.M., Rival, Y.M., Chayer, S., Bourguignon, J.J., Wermuth, C.G., Aminopyridazines as acetylcholinesterase inhibitors. J. Med. Chem. 42 (1999), 730–741.
58. Cordes, T., Vogelsang, J., Tinnefeld, P., On the mechanism of Trolox as antiblinking and antibleaching reagent. J. Am. Chem. Soc. 131 (2009), 5018–5019.
59. Cramer, R.D., The inevitable QSAR renaissance. J. Comput. Aided Mol. Des. 26 (2012), 35–38.
60. Cuajungco, M.P., Faget, K.Y., Zinc takes the center stage: its paradoxical role in Alzheimer's disease. Brain Res. Brain Res. Rev. 41 (2003), 44–56.
61. Cummings, J.L., Treatment of Alzheimer's disease: current and future therapeutic approaches. Rev. Neurol. Dis. 1 (2004), 60–69.
62. Danysz, W., Parsons, C.G., Alzheimer's disease, beta-amyloid, glutamate, NMDA receptors and memantine – searching for the connections. Br. J. Pharmacol. 167 (2012), 324–352.
63. Davalos, A., Gomez-Cordoves, C., Bartolome, B., Extending applicability of the oxygen radical absorbance capacity (ORAC-fluorescein) assay. J. Agric. Food Chem. 52 (2004), 48–54.
64. DeCoster, M.A., Klette, K.L., Knight, E.S., Tortella, F.C., Sigma receptor-mediated neuroprotection against glutamate toxicity in primary rat neuronal cultures. Brain Res. 671 (1995), 45–53.
65. del Pino, J., Ramos, E., Aguilera, O.M., Marco-Contelles, J., Romero, A., Wnt signaling pathway, a potential target for Alzheimer's disease treatment, is activated by a novel multitarget compound ASS234. CNS Neurosci. Ther. 20 (2014), 568–570.
66. Desideri, N., Bolasco, A., Fioravanti, R., Monaco, L.P., Orallo, F., Yanez, M., Ortuso, F., Alcaro, S., Homoisoflavonoids: natural scaffolds with potent and selective monoamine oxidase-B inhibition properties. J. Med. Chem. 54 (2011), 2155–2164.
67. Dewar, M.J.S., Zoebisch, E.G., Healy, E.F., Stewart, J.J.P., Development and use of quantum mechanical molecular models, 76. AM1: a new general purpose quantum mechanical molecular model. J. Am. Chem. Soc. 107 (1985), 3902–3909.
68. Di, L., Kerns, E.H., Fan, K., McConnell, O.J., Carter, G.T., High throughput artificial membrane permeability assay for blood-brain barrier. Eur. J. Med. Chem. 38 (2003), 223–232.
69. Di Pietro, O., Viayna, E., Vicente-Garcia, E., Bartolini, M., Ramon, R., Juarez-Jimenez, J., Clos, M.V., Perez, B., Andrisano, V., Luque, F.J., Lavilla, R., Munoz-Torrero, D., 1,2,3,4-Tetrahydrobenzo[h][1,6]naphthyridines as a new family of potent peripheral-to-midgorge-site inhibitors of acetylcholinesterase: synthesis, pharmacological evaluation and mechanistic studies. Eur. J. Med. Chem. 73 (2014), 141–152.
70. Eckroat, T.J., Green, K.D., Reed, R.A., Bornstein, J.J., Garneau-Tsodikova, S., Investigation of the role of linker moieties in bifunctional tacrine hybrids. Bioorg. Med. Chem. 21 (2013), 3614–3623.
71. Esquivias-Perez, M., Maalej, E., Romero, A., Chabchoub, F., Samadi, A., Marco-Contelles, J., Oset-Gasque, M.J., Nontoxic and neuroprotective beta-naphthotacrines for Alzheimer's disease. Chem. Res. Toxicol. 26 (2013), 986–992.
72. Esteban, G., Allan, J., Samadi, A., Mattevi, A., Unzeta, M., Marco-Contelles, J., Binda, C., Ramsay, R.R., Kinetic and structural analysis of the irreversible inhibition of human monoamine oxidases by ASS234, a multi-target compound designed for use in Alzheimer's disease. Biochim. Biophys. Acta 1844 (2014), 1104–1110.
73. Fang, L., Appenroth, D., Decker, M., Kiehntopf, M., Lupp, A., Peng, S., Fleck, C., Zhang, Y., Lehmann, J., NO-donating tacrine hybrid compounds improve scopolamine-induced cognition impairment and show less hepatotoxicity. J. Med. Chem. 51 (2008), 7666–7669.
74. Fang, L., Appenroth, D., Decker, M., Kiehntopf, M., Roegler, C., Deufel, T., Fleck, C., Peng, S., Zhang, Y., Lehmann, J., Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates. J. Med. Chem. 51 (2008), 713–716.
75. Fang, L., Kraus, B., Lehmann, J., Heilmann, J., Zhang, Y., Decker, M., Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates. Bioorg. Med. Chem. Lett. 18 (2008), 2905–2909.
76. Fernandez-Bachiller, M.I., Perez, C., Monjas, L., Rademann, J., Rodriguez-Franco, M.I., New tacrine-4-oxo-4H-chromene hybrids as multifunctional agents for the treatment of Alzheimer's disease, with cholinergic, antioxidant, and beta-amyloid-reducing properties. J. Med. Chem. 55 (2012), 1303–1317.
77. Ferrari, D., Yang, L.H., Miles, E.W., Dunn, M.F., Beta D305A mutant of tryptophan synthase shows strongly perturbed allosteric regulation and substrate specificity. Biochemistry 40 (2001), 7421–7432.
78. Finberg, J.P., Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release. Pharmacol. Ther. 143 (2014), 133–152.
79. Frost, D., Meechoovet, B., Wang, T., Gately, S., Giorgetti, M., Shcherbakova, I., Dunckley, T., beta-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer's disease-related sites. PLoS ONE, 6, 2011, e19264.
80. Galdeano, C., Viayna, E., Sola, I., Formosa, X., Camps, P., Badia, A., Clos, M.V., Relat, J., Ratia, M., Bartolini, M., Mancini, F., Andrisano, V., Salmona, M., Minguillon, C., Gonzalez-Munoz, G.C., Rodriguez-Franco, M.I., Bidon-Chanal, A., Luque, F.J., Munoz-Torrero, D., Huprine-tacrine heterodimers as anti-amyloidogenic compounds of potential interest against Alzheimer's and prion diseases. J. Med. Chem. 55 (2012), 661–669.
81. Gemma, S., Brogi, S., Patil, P.R., Giovani, S., Lamponi, S., Cappelli, A., Novellino, E., Brown, A., Higgins, M.K., Mustafa, K., Szestak, T., Craig, A.G., Campiani, G., Butini, S., Brindisi, M., From (+)-epigallocatechin gallate to a simplified synthetic analogue as a cytoadherence inhibitor for P. falciparum. RSC Adv. 4 (2014), 4769–4781.
82. Gharaghani, S., Khayamian, T., Ebrahimi, M., Molecular dynamics simulation study and molecular docking descriptors in structure-based QSAR on acetylcholinesterase (AChE) inhibitors. SAR QSAR Environ. Res. 24 (2013), 773–794.
83. GhattyVenkataKrishna, P., Chavali, N., Uberbacher, E., Flexibility of active-site gorge aromatic residues and non-gorge aromatic residues in acetylcholinesterase. Chemical Papers, 2013, 677.
84. Ghosh, A.K., Brindisi, M., Yen, Y.-C., Xu, X., Huang, X., Devasamudram, T., Bilcer, G., Lei, H., Koelsch, G., Mesecar, A., Tang, J., Structure-based design, synthesis and biological evaluation of novel β-secretase inhibitors containing a pyrazole or thiazole moiety as the P3 ligand. Bioorg. Med. Chem. Lett. 25 (2015), 668–672.
85. Giovani, S., Penzo, M., Brogi, S., Brindisi, M., Gemma, S., Novellino, E., Savini, L., Blackman, M.J., Campiani, G., Butini, S., Rational design of the first difluorostatone-based PfSUB1 inhibitors. Bioorg. Med. Chem. Lett. 24 (2014), 3582–3586.
86. Glennon, R.A., Ablordeppey, S.Y., Ismaiel, A.M., el-Ashmawy, M.B., Fischer, J.B., Howie, K.B., Structural features important for sigma 1 receptor binding. J. Med. Chem. 37 (1994), 1214–1219.
87. Grant, B.F., Harford, T.C., Dawson, D.A., Chou, P.S., Pickering, R.P., The Alcohol Use Disorder and Associated Disabilities Interview schedule (AUDADIS): reliability of alcohol and drug modules in a general population sample. Drug Alcohol Depend. 39 (1995), 37–44.
88. Greig, N.H., Utsuki, T., Ingram, D.K., Wang, Y., Pepeu, G., Scali, C., Yu, Q.S., Mamczarz, J., Holloway, H.W., Giordano, T., Chen, D., Furukawa, K., Sambamurti, K., Brossi, A., Lahiri, D.K., Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 17213–17218.
89. Gupta, S., Fallarero, A., Jarvinen, P., Karlsson, D., Johnson, M.S., Vuorela, P.M., Mohan, C.G., Discovery of dual binding site acetylcholinesterase inhibitors identified by pharmacophore modeling and sequential virtual screening techniques. Bioorg. Med. Chem. Lett. 21 (2011), 1105–1112.
90. Hajjo, R., Grulke, C.M., Golbraikh, A., Setola, V., Huang, X.P., Roth, B.L., Tropsha, A., Development, validation, and use of quantitative structure–activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs. J. Med. Chem. 53 (2010), 7573–7586.
91. Hajjo, R., Setola, V., Roth, B.L., Tropsha, A., Chemocentric informatics approach to drug discovery: identification and experimental validation of selective estrogen receptor modulators as ligands of 5-hydroxytryptamine-6 receptors and as potential cognition enhancers. J. Med. Chem. 55 (2012), 5704–5719.
92. Hamley, I.W., The amyloid beta peptide: a chemist's perspective. Role in Alzheimer's and fibrillization. Chem. Rev. 112 (2012), 5147–5192.
93. Hamulakova, S., Janovec, L., Hrabinova, M., Spilovska, K., Korabecny, J., Kristian, P., Kuca, K., Imrich, J., Synthesis and biological evaluation of novel tacrine derivatives and tacrine-coumarin hybrids as cholinesterase inhibitors. J. Med. Chem. 57 (2014), 7073–7084.
94. Hansch, C., Maloney, P.P., Fujita, T., Muir, R.M., Correlation of biological activity of phenoxyacetic acids with Hammett substituent constants and partition coefficients. Nature 194 (1962), 178–180.
95. Harel, M., Schalk, I., Ehret-Sabatier, L., Bouet, F., Goeldner, M., Hirth, C., Axelsen, P.H., Silman, I., Sussman, J.L., Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc. Natl. Acad. Sci. U. S. A. 90 (1993), 9031–9035.
96. Haubmann, C., Hubner, H., Gmeiner, P., Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg. Med. Chem. Lett. 9 (1999), 3143–3146.
97. Hellewell, S.B., Bruce, A., Feinstein, G., Orringer, J., Williams, W., Bowen, W.D., Rat liver and kidney contain high densities of sigma 1 and sigma 2 receptors: characterization by ligand binding and photoaffinity labeling. Eur. J. Pharmacol. 268 (1994), 9–18.
98. Henchman, R.H., McCammon, J.A., Structural and dynamic properties of water around acetylcholinesterase. Protein Sci. 11 (2002), 2080–2090.
99. Henchman, R.H., Tai, K., Shen, T., McCammon, J.A., Properties of water molecules in the active site gorge of acetylcholinesterase from computer simulation. Biophys. J. 82 (2002), 2671–2682.
100. Hom, R.K., Gailunas, A.F., Mamo, S., Fang, L.Y., Tung, J.S., Walker, D.E., Davis, D., Thorsett, E.D., Jewett, N.E., Moon, J.B., John, V., Design and synthesis of hydroxyethylene-based peptidomimetic inhibitors of human beta-secretase. J. Med. Chem. 47 (2004), 158–164.
101. Hong, L., Koelsch, G., Lin, X., Wu, S., Terzyan, S., Ghosh, A.K., Zhang, X.C., Tang, J., Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science (New York, N Y) 290 (2000), 150–153.
102. Hu, Y., Zhang, J., Chandrashankra, O., Ip, F.C., Ip, N.Y., Design, synthesis and evaluation of novel heterodimers of donepezil and huperzine fragments as acetylcholinesterase inhibitors. Bioorg. Med. Chem. 21 (2013), 676–683.
103. Huang, W., Tang, L., Shi, Y., Huang, S., Xu, L., Sheng, R., Wu, P., Li, J., Zhou, N., Hu, Y., Searching for the multi-target-directed ligands against Alzheimer's disease: discovery of quinoxaline-based hybrid compounds with AChE, H(3)R and BACE 1 inhibitory activities. Bioorg. Med. Chem. 19 (2011), 7158–7167.
104. Huang, Y., Hammond, P.S., Whirrett, B.R., Kuhner, R.J., Wu, L., Childers, S.R., Mach, R.H., Synthesis and quantitative structure–activity relationships of N-(1-benzylpiperidin-4-yl)phenylacetamides and related analogues as potent and selective sigma1 receptor ligands. J. Med. Chem. 41 (1998), 2361–2370.
105. Huang, Y., Hammond, P.S., Wu, L., Mach, R.H., Synthesis and structure–activity relationships of N-(1-benzylpiperidin-4-yl)arylacetamide analogues as potent sigma1 receptor ligands. J. Med. Chem. 44 (2001), 4404–4415.
106. Huang, Y., Luedtke, R.R., Freeman, R.A., Wu, L., Mach, R.H., Synthesis of 2-(2,3-dimethoxyphenyl)-4-(aminomethyl)imidazole analogues and their binding affinities for dopamine D(2) and D(3) receptors. Bioorg. Med. Chem. 9 (2001), 3113–3122.
107. Huang, Y., Zheng, L., Halliday, G., Dobson-Stone, C., Wang, Y., Tang, H.D., Cao, L., Deng, Y.L., Wang, G., Zhang, Y.M., Wang, J.H., Hallupp, M., Kwok, J., Chen, S.D., Genetic polymorphisms in sigma-1 receptor and apolipoprotein E interact to influence the severity of Alzheimer's disease. Curr. Alzheimer Res. 8 (2011), 765–770.
108. Hui, A.-L., Chen, Y., Zhu, S.-J., Gan, C.-S., Pan, J., Zhou, A., Design and synthesis of tacrine-phenothiazine hybrids as multitarget drugs for Alzheimer's disease. Med. Chem. Res. 23 (2014), 3546–3557.
109. Kamei, H., Noda, Y., Kameyama, T., Nabeshima, T., Role of (+)-SKF-10,047-sensitive sub-population of sigma 1 receptors in amelioration of conditioned fear stress in rats: association with mesolimbic dopaminergic systems. Eur. J. Pharmacol. 319 (1997), 165–172.
110. Karplus, M., McCammon, J.A., Molecular dynamics simulations of biomolecules. Nat. Struct. Biol. 9 (2002), 646–652.
111. Kawakami, Y., Inoue, A., Kawai, T., Wakita, M., Sugimoto, H., Hopfinger, A.J., The rationale for E2020 as a potent acetylcholinesterase inhibitor. Bioorg. Med. Chem. 4 (1996), 1429–1446.
112. Keri, R.S., Quintanova, C., Marques, S.M., Esteves, A.R., Cardoso, S.M., Santos, M.A., Design, synthesis and neuroprotective evaluation of novel tacrine-benzothiazole hybrids as multi-targeted compounds against Alzheimer's disease. Bioorg. Med. Chem. 21 (2013), 4559–4569.
113. Kerwin, J.F. Jr., Lancaster, J.R. Jr., Feldman, P.L., Nitric oxide: a new paradigm for second messengers. J. Med. Chem. 38 (1995), 4343–4362.
114. Kochi, A., Eckroat, T.J., Green, K.D., Mayhoub, A.S., Lim, M.H., Garneau-Tsodikova, S., A novel hybrid of 6-chlorotacrine and metal-amyloid-[small beta] modulator for inhibition of acetylcholinesterase and metal-induced amyloid-[small beta] aggregation. Chem. Sci. 4 (2013), 4137–4145.
115. Kua, J., Zhang, Y., Eslami, A.C., Butler, J.R., McCammon, J.A., Studying the roles of W86, E202, and Y337 in binding of acetylcholine to acetylcholinesterase using a combined molecular dynamics and multiple docking approach. Protein Sci. 12 (2003), 2675–2684.
116. Kua, J., Zhang, Y., McCammon, J.A., Studying enzyme binding specificity in acetylcholinesterase using a combined molecular dynamics and multiple docking approach. J. Am. Chem. Soc. 124 (2002), 8260–8267.
117. Lagadic-Gossmann, D., Rissel, M., Le Bot, M.A., Guillouzo, A., Toxic effects of tacrine on primary hepatocytes and liver epithelial cells in culture. Cell Biol. Toxicol. 14 (1998), 361–373.
118. Lakshmi, V., Kannan, V.S., Boopathy, R., Identification of potential bivalent inhibitors from natural compounds for acetylcholinesterase through in silico screening using multiple pharmacophores. J. Mol. Graph. Model. 40 (2013), 72–79.
119. Lan, J.S., Xie, S.S., Li, S.Y., Pan, L.F., Wang, X.B., Kong, L.Y., Design, synthesis and evaluation of novel tacrine-(beta-carboline) hybrids as multifunctional agents for the treatment of Alzheimer's disease. Bioorg. Med. Chem. 22 (2014), 6089–6104.
120. Lauren, J., Gimbel, D.A., Nygaard, H.B., Gilbert, J.W., Strittmatter, S.M., Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457 (2009), 1128–1132.
121. Laurini, E., Marson, D., Dal Col, V., Fermeglia, M., Mamolo, M.G., Zampieri, D., Vio, L., Pricl, S., Another brick in the wall. Validation of the sigma1 receptor 3D model by computer-assisted design, synthesis, and activity of new sigma1 ligands. Mol. Pharm. 9 (2012), 3107–3126.
122. Lecoutey, C., Rochais, C., Genest, D., Butt-Gueulle, S., Ballandonne, C., Corvaisier, S., Dulin, F., Lepailleur, A., Sopkova-de Oliveira Santos, J., Dallemagne, P., Synthesis of dual AChE/5-HT4 receptor multi-target directed ligands. Med. Chem. Commun. 3 (2012), 627–634.
123. Leon, R., Garcia, A.G., Marco-Contelles, J., Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease. Med. Res. Rev. 33 (2013), 139–189.
124. Li, S.Y., Jiang, N., Xie, S.S., Wang, K.D., Wang, X.B., Kong, L.Y., Design, synthesis and evaluation of novel tacrine-rhein hybrids as multifunctional agents for the treatment of Alzheimer's disease. Org. Biomol. Chem. 12 (2014), 801–814.
125. Li, S.Y., Wang, X.B., Xie, S.S., Jiang, N., Wang, K.D., Yao, H.Q., Sun, H.B., Kong, L.Y., Multifunctional tacrine-flavonoid hybrids with cholinergic, beta-amyloid-reducing, and metal chelating properties for the treatment of Alzheimer's disease. Eur. J. Med. Chem. 69 (2013), 632–646.
126. Li, Y.P., Weng, X., Ning, F.X., Ou, J.B., Hou, J.Q., Luo, H.B., Li, D., Huang, Z.S., Huang, S.L., Gu, L.Q., 3D-QSAR studies of azaoxoisoaporphine, oxoaporphine, and oxoisoaporphine derivatives as anti-AChE and anti-AD agents by the CoMFA method. J. Mol. Graph. Model. 41 (2013), 61–67.
127. Lu, C., Zhou, Q., Yan, J., Du, Z., Huang, L., Li, X., A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease. Eur. J. Med. Chem. 62 (2013), 745–753.
128. Luo, W., Li, Y.P., He, Y., Huang, S.L., Li, D., Gu, L.Q., Huang, Z.S., Synthesis and evaluation of heterobivalent tacrine derivatives as potential multi-functional anti-Alzheimer agents. Eur. J. Med. Chem. 46 (2011), 2609–2616.
129. Luo, X., Yan, R., Inhibition of BACE1 for therapeutic use in Alzheimer's disease. Int. J. Clin. Exp. Pathol. 3 (2010), 618–628.
130. Luo, Z., Sheng, J., Sun, Y., Lu, C., Yan, J., Liu, A., Luo, H.B., Huang, L., Li, X., Synthesis and evaluation of multi-target-directed ligands against Alzheimer's disease based on the fusion of donepezil and ebselen. J. Med. Chem. 56 (2013), 9089–9099.
131. Lushchekina, S.V., Nemukhin, A.V., Morozov, D.I., Varfolomeev, S.D., Correlation between the substrate structure and the rate of acetylcholinesterase hydrolysis modeled with the combined quantum mechanical/molecular mechanical studies. Chem. Biol. Interact. 187 (2010), 59–63.
132. Maalej, E., Chabchoub, F., Oset-Gasque, M.J., Esquivias-Perez, M., Gonzalez, M.P., Monjas, L., Perez, C., de los Rios, C., Rodriguez-Franco, M.I., Iriepa, I., Moraleda, I., Chioua, M., Romero, A., Marco-Contelles, J., Samadi, A., Synthesis, biological assessment, and molecular modeling of racemic 7-aryl-9,10,11,12-tetrahydro-7H-benzo[7,8]chromeno[2,3-b]quinolin-8-amines as potential drugs for the treatment of Alzheimer's disease. Eur. J. Med. Chem. 54 (2012), 750–763.
133. Maalej, E., Chabchoub, F., Samadi, A., de los Rios, C., Perona, A., Morreale, A., Marco-Contelles, J., Synthesis, biological assessment and molecular modeling of 14-aryl-10,11,12,14-tetrahydro-9H-benzo[5,6]chromeno[2,3-b]quinolin-13-amines. Bioorg. Med. Chem. Lett. 21 (2011), 2384–2388.
134. Mao, F., Chen, J., Zhou, Q., Luo, Z., Huang, L., Li, X., Novel tacrine-ebselen hybrids with improved cholinesterase inhibitory, hydrogen peroxide and peroxynitrite scavenging activity. Bioorg. Med. Chem. Lett. 23 (2013), 6737–6742.
135. Martin, W.R., Eades, C.G., Thompson, J.A., Huppler, R.E., Gilbert, P.E., The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 197 (1976), 517–532.
136. Matsutomo, T., Stark, T.D., Hofmann, T., In vitro activity-guided identification of antioxidants in aged garlic extract. J. Agric. Food Chem. 61 (2013), 3059–3067.
137. Maurice, T., Privat, A., SA4503, a novel cognitive enhancer with sigma1 receptor agonist properties, facilitates NMDA receptor-dependent learning in mice. Eur. J. Pharmacol. 328 (1997), 9–18.
138. Maurice, T., Su, T.P., The pharmacology of sigma-1 receptors. Pharmacol. Ther. 124 (2009), 195–206.
139. Mishina, M., Ishiwata, K., Ishii, K., Kitamura, S., Kimura, Y., Kawamura, K., Oda, K., Sasaki, T., Sakayori, O., Hamamoto, M., Kobayashi, S., Katayama, Y., Function of sigma1 receptors in Parkinson's disease. Acta Neurol. Scand. 112 (2005), 103–107.
140. Mishra, N., Basu, A., Exploring different virtual screening strategies for acetylcholinesterase inhibitors. Biomed. Res. Int., 2013, 2013, 236850.
141. Mohamed, T., Yeung, J.C., Vasefi, M.S., Beazely, M.A., Rao, P.P., Development and evaluation of multifunctional agents for potential treatment of Alzheimer's disease: application to a pyrimidine-2,4-diamine template. Bioorg. Med. Chem. Lett. 22 (2012), 4707–4712.
142. Mount, C., Downton, C., Alzheimer disease: progress or profit?. Nat. Med. 12 (2006), 780–784.
143. Naito, Y., Yoshikawa, T., Tanigawa, T., Sakurai, K., Yamasaki, K., Uchida, M., Kondo, M., Hydroxyl radical scavenging by rebamipide and related compounds: electron paramagnetic resonance study. Free Radic. Biol. Med. 18 (1995), 117–123.
144. Nakazawa, M., Matsuno, K., Mita, S., Activation of sigma1 receptor subtype leads to neuroprotection in the rat primary neuronal cultures. Neurochem. Int. 32 (1998), 337–343.
145. Nasica-Labouze, J., Nguyen, P.H., Sterpone, F., Berthoumieu, O., Buchete, N.V., Cote, S., De Simone, A., Doig, A.J., Faller, P., Garcia, A., Laio, A., Li, M.S., Melchionna, S., Mousseau, N., Mu, Y., Paravastu, A., Pasquali, S., Rosenman, D.J., Strodel, B., Tarus, B., Viles, J.H., Zhang, T., Wang, C., Derreumaux, P., Amyloid beta protein and Alzheimer's disease: when computer simulations complement experimental studies. Chem. Rev. 115 (2015), 3518–3563.
146. Nepovimova, E., Uliassi, E., Korabecny, J., Pena-Altamira, L.E., Samez, S., Pesaresi, A., Garcia, G.E., Bartolini, M., Andrisano, V., Bergamini, C., Fato, R., Lamba, D., Roberti, M., Kuca, K., Monti, B., Bolognesi, M.L., Multitarget drug design strategy: quinone-tacrine hybrids designed to block amyloid-beta aggregation and to exert anticholinesterase and antioxidant effects. J. Med. Chem. 57 (2014), 8576–8589.
147. Ning, X., Rangwala, H., Karypis, G., Multi-assay-based structure–activity relationship models: improving structure–activity relationship models by incorporating activity information from related targets. J. Chem. Inf. Model. 49 (2009), 2444–2456.
148. Niu, C., Xu, Y., Luo, X., Duan, W., Silman, I., Sussman, J.L., Zhu, W., Chen, K., Shen, J., Jiang, H., Dynamic mechanism of E2020 binding to acetylcholinesterase: a steered molecular dynamics simulation. J. Phys. Chem. B 109 (2005), 23730–23738.
149. O'Leary, J.C. II, Li, Q., Marinec, P., Blair, L.J., Congdon, E.E., Johnson, A.G., Jinwal, U.K., Koren, J. III, Jones, J.R., Kraft, C., Peters, M., Abisambra, J.F., Duff, K.E., Weeber, E.J., Gestwicki, J.E., Dickey, C.A., Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden. Mol. Neurodegener., 5, 2010, 45.
150. Ozturan Ozer, E., Tan, O.U., Ozadali, K., Kucukkilinc, T., Balkan, A., Ucar, G., Synthesis, molecular modeling and evaluation of novel N′-2-(4-benzylpiperidin-/piperazin-1-yl)acylhydrazone derivatives as dual inhibitors for cholinesterases and Abeta aggregation. Bioorg. Med. Chem. Lett. 23 (2013), 440–443.
151. Pasquini, S., Mugnaini, C., Ligresti, A., Tafi, A., Brogi, S., Falciani, C., Pedani, V., Pesco, N., Guida, F., Luongo, L., Varani, K., Borea, P.A., Maione, S., Di Marzo, V., Corelli, F., Design, synthesis, and pharmacological characterization of indol-3-ylacetamides, indol-3-yloxoacetamides, and indol-3-ylcarboxamides: potent and selective CB2 cannabinoid receptor inverse agonists. J. Med. Chem. 55 (2012), 5391–5402.
152. Patocka, J., Jun, D., Kuca, K., Possible role of hydroxylated metabolites of tacrine in drug toxicity and therapy of Alzheimer's disease. Curr. Drug Metab. 9 (2008), 332–335.
153. Peng, D.Y., Sun, Q., Zhu, X.L., Lin, H.Y., Chen, Q., Yu, N.X., Yang, W.C., Yang, G.F., Acetylcholinesterase inhibitors with multi-functions on butylcholinesterase, Aβ aggregation, and β-secretase. Bioorg. Med. Chem. 20 (2012), 6739–7675.
154. Perez, V., Marco-Contelles, J.L., Fernandez-Alvarez, E., Unzeta, M., Relevance of benzyloxy group in 2-indolyl methylamines in the selective MAO-B inhibition. Br. J. Pharmacol. 127 (1999), 869–876.
155. Pi, R., Mao, X., Chao, X., Cheng, Z., Liu, M., Duan, X., Ye, M., Chen, X., Mei, Z., Liu, P., Li, W., Han, Y., Tacrine-6-ferulic acid, a novel multifunctional dimer, inhibits amyloid-beta-mediated Alzheimer's disease-associated pathogenesis in vitro and in vivo. PLoS ONE, 7, 2012, e31921.
156. Podoly, E., Shalev, D.E., Shenhar-Tsarfaty, S., Bennett, E.R., Ben Assayag, E., Wilgus, H., Livnah, O., Soreq, H., The butyrylcholinesterase K variant confers structurally derived risks for Alzheimer pathology. J. Biol. Chem. 284 (2009), 17170–17179.
157. Prezzavento, O., Arena, E., Parenti, C., Pasquinucci, L., Arico, G., Scoto, G.M., Grancara, S., Toninello, A., Ronsisvalle, S., Design and synthesis of new bifunctional sigma-1 selective ligands with antioxidant activity. J. Med. Chem. 56 (2013), 2447–2455.
158. Pudlo, M., Luzet, V., Ismaili, L., Tomassoli, I., Iutzeler, A., Refouvelet, B., Quinolone-benzylpiperidine derivatives as novel acetylcholinesterase inhibitor and antioxidant hybrids for Alzheimer disease. Bioorg. Med. Chem. 22 (2014), 2496–2507.
159. Qian, S., He, L., Mak, M., Han, Y., Ho, C.Y., Zuo, Z., Synthesis, biological activity, and biopharmaceutical characterization of tacrine dimers as acetylcholinesterase inhibitors. Int. J. Pharm. 477 (2014), 442–453.
160. Qizilbash, N., Birks, J., Lopez Arrieta, J., Lewington, S., Szeto, S., WITHDRAWN: Tacrine for Alzheimer's disease. Cochrane Database Syst. Rev., 2007, CD000202.
161. Razavi, S.F., Khoobi, M., Nadri, H., Sakhteman, A., Moradi, A., Emami, S., Foroumadi, A., Shafiee, A., Synthesis and evaluation of 4-substituted coumarins as novel acetylcholinesterase inhibitors. Eur. J. Med. Chem. 64 (2013), 252–259.
162. Reid, G.A., Chilukuri, N., Darvesh, S., Butyrylcholinesterase and the cholinergic system. Neuroscience 234 (2013), 53–68.
163. Remya, C., Dileep, K.V., Tintu, I., Variyar, E.J., Sadasivan, C., In vitro inhibitory profile of NDGA against AChE and its in silico structural modifications based on ADME profile. J. Mol. Model. 19 (2013), 1179–1194.
164. Richmond, V., Murray, A.P., Maier, M.S., Synthesis and acetylcholinesterase inhibitory activity of polyhydroxylated sulfated steroids: structure/activity studies. Steroids 78 (2013), 1141–1147.
165. Rodrigues Simoes, M.C., Dias Viegas, F.P., Moreira, M.S., de Freitas Silva, M., Riquiel, M.M., da Rosa, P.M., Castelli, M.R., dos Santos, M.H., Soares, M.G., Viegas, C. Jr., Donepezil: an important prototype to the design of new drug candidates for Alzheimer's disease. Mini Rev. Med. Chem. 14 (2014), 2–19.
166. Rodriguez-Franco, M.I., Fernandez-Bachiller, M.I., Perez, C., Castro, A., Martinez, A., Design and synthesis of N-benzylpiperidine-purine derivatives as new dual inhibitors of acetyl- and butyrylcholinesterase. Bioorg. Med. Chem. 13 (2005), 6795–6802.
167. Romero, A., Cacabelos, R., Oset-Gasque, M.J., Samadi, A., Marco-Contelles, J., Novel tacrine-related drugs as potential candidates for the treatment of Alzheimer's disease. Bioorg. Med. Chem. Lett. 23 (2013), 1916–1922.
168. Rook, Y., Schmidtke, K.U., Gaube, F., Schepmann, D., Wunsch, B., Heilmann, J., Lehmann, J., Winckler, T., Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J. Med. Chem. 53 (2010), 3611–3617.
169. Rosini, M., Simoni, E., Minarini, A., Melchiorre, C., Multi-target design strategies in the context of Alzheimer's disease: acetylcholinesterase inhibition and NMDA receptor antagonism as the driving forces. Neurochem. Res. 39 (2014), 1914–1923.
170. Sadowski, M., Wisniewski, T., Disease modifying approaches for Alzheimer's pathology. Curr. Pharm. Des. 13 (2007), 1943–1954.
171. Samadi, A., Chioua, M., Bolea, I., de Los Rios, C., Iriepa, I., Moraleda, I., Bastida, A., Esteban, G., Unzeta, M., Galvez, E., Marco-Contelles, J., Synthesis, biological assessment and molecular modeling of new multipotent MAO and cholinesterase inhibitors as potential drugs for the treatment of Alzheimer's disease. Eur. J. Med. Chem. 46 (2011), 4665–4668.
172. Samadi, A., de la Fuente Revenga, M., Perez, C., Iriepa, I., Moraleda, I., Rodriguez-Franco, M.I., Marco-Contelles, J., Synthesis, pharmacological assessment, and molecular modeling of 6-chloro-pyridonepezils: new dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease. Eur. J. Med. Chem. 67 (2013), 64–74.
173. Samadi, A., de los Rios, C., Bolea, I., Chioua, M., Iriepa, I., Moraleda, I., Bartolini, M., Andrisano, V., Galvez, E., Valderas, C., Unzeta, M., Marco-Contelles, J., Multipotent MAO and cholinesterase inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine. Eur. J. Med. Chem. 52 (2012), 251–262.
174. Samadi, A., Marco-Contelles, J., Soriano, E., Alvarez-Perez, M., Chioua, M., Romero, A., Gonzalez-Lafuente, L., Gandia, L., Roda, J.M., Lopez, M.G., Villarroya, M., Garcia, A.G., Rios Cde, L., Multipotent drugs with cholinergic and neuroprotective properties for the treatment of Alzheimer and neuronal vascular diseases I. Synthesis, biological assessment, and molecular modeling of simple and readily available 2-aminopyridine-, and 2-chloropyridine-3,5-dicarbonitriles. Bioorg. Med. Chem. 18 (2010), 5861–5872.
175. Sanson, B., Colletier, J.P., Xu, Y., Lang, P.T., Jiang, H., Silman, I., Sussman, J.L., Weik, M., Backdoor opening mechanism in acetylcholinesterase based on X-ray crystallography and molecular dynamics simulations. Protein Sci. 20 (2011), 1114–1118.
176. Savini, L., Gaeta, A., Fattorusso, C., Catalanotti, B., Campiani, G., Chiasserini, L., Pellerano, C., Novellino, E., McKissic, D., Saxena, A., Specific targeting of acetylcholinesterase and butyrylcholinesterase recognition sites. Rational design of novel, selective, and highly potent cholinesterase inhibitors. J. Med. Chem. 46 (2003), 1–4.
177. Schott, Y., Decker, M., Rommelspacher, H., Lehmann, J., 6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. Bioorg. Med. Chem. Lett. 16 (2006), 5840–5843.
178. Senda, T., Matsuno, K., Kobayashi, T., Nakazawa, M., Nakata, K., Mita, S., Ameliorative effect of SA4503, a novel cognitive enhancer, on the basal forebrain lesion-induced impairment of the spatial learning performance in rats. Pharmacol. Biochem. Behav. 59 (1998), 129–134.
179. Senda, T., Matsuno, K., Okamoto, K., Kobayashi, T., Nakata, K., Mita, S., Ameliorating effect of SA4503, a novel sigma 1 receptor agonist, on memory impairments induced by cholinergic dysfunction in rats. Eur. J. Pharmacol. 315 (1996), 1–10.
180. Shao, D., Zou, C., Luo, C., Tang, X., Li, Y., Synthesis and evaluation of tacrine-E2020 hybrids as acetylcholinesterase inhibitors for the treatment of Alzheimer's disease. Bioorg. Med. Chem. Lett. 14 (2004), 4639–4642.
181. Shen, T., Tai, K., Henchman, R.H., McCammon, J.A., Molecular dynamics of acetylcholinesterase. Acc. Chem. Res. 35 (2002), 332–340.
182. Sheng, R., Lin, X., Li, J., Jiang, Y., Shang, Z., Hu, Y., Design, synthesis, and evaluation of 2-phenoxy-indan-1-one derivatives as acetylcholinesterase inhibitors. Bioorg. Med. Chem. Lett. 15 (2005), 3834–3837.
183. Shi, J., Tai, K., McCammon, J.A., Taylor, P., Johnson, D.A., Nanosecond dynamics of the mouse acetylcholinesterase cys69-cys96 omega loop. J. Biol. Chem. 278 (2003), 30905–30911.
184. Silva, D., Chioua, M., Samadi, A., Agostinho, P., Garcao, P., Lajarin-Cuesta, R., de Los Rios, C., Iriepa, I., Moraleda, I., Gonzalez-Lafuente, L., Mendes, E., Perez, C., Rodriguez-Franco, M.I., Marco-Contelles, J., Carmo Carreiras, M., Synthesis, pharmacological assessment, and molecular modeling of acetylcholinesterase/butyrylcholinesterase inhibitors: effect against amyloid-beta-induced neurotoxicity. ACS Chem. Neurosci. 4 (2013), 547–565.
185. Sirin, G.S., Zhang, Y., How is acetylcholinesterase phosphonylated by soman? An ab initio QM/MM molecular dynamics study. J. Phys. Chem. A 118 (2014), 9132–9139.
186. Smith, D.G., Cappai, R., Barnham, K.J., The redox chemistry of the Alzheimer's disease amyloid beta peptide. Biochim. Biophys. Acta 1768 (2007), 1976–1990.
187. Song, M.S., Matveychuk, D., MacKenzie, E.M., Duchcherer, M., Mousseau, D.D., Baker, G.B., An update on amine oxidase inhibitors: multifaceted drugs. Prog. Neuropsychopharmacol. Biol. Psychiatry 44 (2013), 118–124.
188. Songsiang, U., Thongthoom, T., Boonyarat, C., Yenjai, C., Claurailas A-D, cytotoxic carbazole alkaloids from the roots of Clausena harmandiana. J. Nat. Prod. 74 (2011), 208–212.
189. Sopkova-de Oliveira Santos, J., Lesnard, A., Agondanou, J.H., Dupont, N., Godard, A.M., Stiebing, S., Rochais, C., Fabis, F., Dallemagne, P., Bureau, R., Rault, S., Virtual screening discovery of new acetylcholinesterase inhibitors issued from CERMN chemical library. J. Chem. Inf. Model. 50 (2010), 422–428.
190. Speck-Planche, A., Luan, F., Cordeiro, M.N., Discovery of anti-Alzheimer agents: current ligand-based approaches toward the design of acetylcholinesterase inhibitors. Mini Rev. Med. Chem. 12 (2012), 583–591.
191. Speck-Planche, A., Luan, F., Cordeiro, M.N., Role of ligand-based drug design methodologies toward the discovery of new anti-Alzheimer agents: futures perspectives in fragment-based ligand design. Curr. Med. Chem. 19 (2012), 1635–1645.
192. Spilovska, K., Korabecny, J., Kral, J., Horova, A., Musilek, K., Soukup, O., Drtinova, L., Gazova, Z., Siposova, K., Kuca, K., 7-Methoxytacrine-adamantylamine heterodimers as cholinesterase inhibitors in Alzheimer's disease treatment – synthesis, biological evaluation and molecular modeling studies. Molecules 18 (2013), 2397–2418.
193. Standridge, J.B., Pharmacotherapeutic approaches to the prevention of Alzheimer's disease. Am. J. Geriatr. Pharmacother. 2 (2004), 119–132.
194. Stasiak, A., Mussur, M., Unzeta, M., Samadi, A., Marco-Contelles, J.L., Fogel, W.A., Effects of novel monoamine oxidases and cholinesterases targeting compounds on brain neurotransmitters and behavior in rat model of vascular dementia. Curr. Pharm. Des. 20 (2014), 161–171.
195. Storr, T., Thompson, K.H., Orvig, C., Design of targeting ligands in medicinal inorganic chemistry. Chem. Soc. Rev. 35 (2006), 534–544.
196. Sugimoto, H., The new approach in development of anti-Alzheimer's disease drugs via the cholinergic hypothesis. Chem. Biol. Interact. 175 (2008), 204–208.
197. Sugimoto, H., Iimura, Y., Yamanishi, Y., Yamatsu, K., Synthesis and anti-acetylcholinesterase activity of 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine hydrochloride (E2020) and related compounds. Bioorg. Med. Chem. Lett. 2 (1992), 871–876.
198. Sugimoto, H., Ogura, H., Arai, Y., Limura, Y., Yamanishi, Y., Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor. Jpn. J. Pharmacol. 89 (2002), 7–20.
199. Sugimoto, H., Tsuchiya, Y., Sugumi, H., Higurashi, K., Karibe, N., Iimura, Y., Sasaki, A., Kawakami, Y., Nakamura, T., Araki, S., et al. Novel piperidine derivatives. Synthesis and anti-acetylcholinesterase activity of 1-benzyl-4-[2-(N-benzoylamino)ethyl]piperidine derivatives. J. Med. Chem. 33 (1990), 1880–1887.
200. Sun, Q., Peng, D.Y., Yang, S.G., Zhu, X.L., Yang, W.C., Yang, G.F., Syntheses of coumarin-tacrine hybrids as dual-site acetylcholinesterase inhibitors and their activity against butylcholinesterase, Aβ aggregation, and beta-secretase. Bioorg. Med. Chem. 22 (2014), 4784–4791.
201. Sun, X., Zhang, P., Pi, R., Zhou, Y., Deng, X., Xie, Z., Liao, Q., Determination of tacrine-6-ferulic acid in rat plasma by LC–MS/MS and its application to pharmacokinetics study. Biomed. Chromatogr. 28 (2014), 1352–1359.
202. Sun, Y., Chen, J., Chen, X., Huang, L., Li, X., Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine–Homoisoflavonoid hybrids. Bioorg. Med. Chem. 21 (2013), 7406–7417.
203. Tang, H., Ning, F.X., Wei, Y.B., Huang, S.L., Huang, Z.S., Chan, A.S., Gu, L.Q., Derivatives of oxoisoaporphine alkaloids: a novel class of selective acetylcholinesterase inhibitors. Bioorg. Med. Chem. Lett. 17 (2007), 3765–3768.
204. Tang, H., Zhao, L.Z., Zhao, H.T., Huang, S.L., Zhong, S.M., Qin, J.K., Chen, Z.F., Huang, Z.S., Liang, H., Hybrids of oxoisoaporphine-tacrine congeners: novel acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation inhibitors. Eur. J. Med. Chem. 46 (2011), 4970–4979.
205. Taniguchi, S., Suzuki, N., Masuda, M., Hisanaga, S., Iwatsubo, T., Goedert, M., Hasegawa, M., Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J. Biol. Chem. 280 (2005), 7614–7623.
206. Tchedre, K.T., Yorio, T., Sigma-1 receptors protect RGC-5 cells from apoptosis by regulating intracellular calcium, Bax levels, and caspase-3 activation. Invest. Ophthalmol. Vis. Sci. 49 (2008), 2577–2588.
207. Thathiah, A., De Strooper, B., The role of G protein-coupled receptors in the pathology of Alzheimer's disease. Nat. Rev. Neurosci. 12 (2011), 73–87.
208. Thiratmatrakul, S., Yenjai, C., Waiwut, P., Vajragupta, O., Reubroycharoen, P., Tohda, M., Boonyarat, C., Synthesis, biological evaluation and molecular modeling study of novel tacrine-carbazole hybrids as potential multifunctional agents for the treatment of Alzheimer's disease. Eur. J. Med. Chem. 75 (2014), 21–30.
209. Thomas, D.D., Ridnour, L.A., Isenberg, J.S., Flores-Santana, W., Switzer, C.H., Donzelli, S., Hussain, P., Vecoli, C., Paolocci, N., Ambs, S., Colton, C.A., Harris, C.C., Roberts, D.D., Wink, D.A., The chemical biology of nitric oxide: implications in cellular signaling. Free Radic. Biol. Med. 45 (2008), 18–31.
210. Valasani, K.R., Chaney, M.O., Day, V.W., Shidu Yan, S., Acetylcholinesterase inhibitors: structure based design, synthesis, pharmacophore modeling, and virtual screening. J. Chem. Inf. Model. 53 (2013), 2033–2046.
211. Venugopal, C., Demos, C.M., Rao, K.S., Pappolla, M.A., Sambamurti, K., Beta-secretase: structure, function, and evolution. CNS Neurol. Disord. Drug Targets 7 (2008), 278–294.
212. Viayna, E., Sola, I., Bartolini, M., De Simone, A., Tapia-Rojas, C., Serrano, F.G., Sabate, R., Juarez-Jimenez, J., Perez, B., Luque, F.J., Andrisano, V., Clos, M.V., Inestrosa, N.C., Munoz-Torrero, D., Synthesis and multitarget biological profiling of a novel family of rhein derivatives as disease-modifying anti-Alzheimer agents. J. Med. Chem. 57 (2014), 2549–2567.
213. Vitorovic-Todorovic, M.D., Koukoulitsa, C., Juranic, I.O., Mandic, L.M., Drakulic, B.J., Structural modifications of 4-aryl-4-oxo-2-aminylbutanamides and their acetyl- and butyrylcholinesterase inhibitory activity. Investigation of AChE-ligand interactions by docking calculations and molecular dynamics simulations. Eur. J. Med. Chem. 81 (2014), 158–175.
214. Walsh, D.M., Selkoe, D.J., A beta oligomers – a decade of discovery. J. Neurochem. 101 (2007), 1172–1184.
215. Wang, L., Esteban, G., Ojima, M., Bautista-Aguilera, O.M., Inokuchi, T., Moraleda, I., Iriepa, I., Samadi, A., Youdim, M.B., Romero, A., Soriano, E., Herrero, R., Fernandez Fernandez, A.P., Ricardo Martinez, M., Marco-Contelles, J., Unzeta, M., Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease. Eur. J. Med. Chem. 80 (2014), 543–561.
216. Wang, Y., Wang, F., Yu, J.P., Jiang, F.C., Guan, X.L., Wang, C.M., Li, L., Cao, H., Li, M.X., Chen, J.G., Novel multipotent phenylthiazole-tacrine hybrids for the inhibition of cholinesterase activity, beta-amyloid aggregation and Ca(2)(+) overload. Bioorg. Med. Chem. 20 (2012), 6513–6522.
217. Watkins, P.B., Zimmerman, H.J., Knapp, M.J., Gracon, S.I., Lewis, K.W., Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. J. Am. Med. Assoc. 271 (1994), 992–998.
218. Wermuth, C.G., Exinger, A., [Morpholinoethylamino-3 methyl-4 phenyl-6 pyridazine dihydrochloride (Agar 1240)]. Agressologie 13 (1972), 285–289.
219. Wieckowska, A., Bajda, M., Guzior, N., Malawska, B., Novel alkyl- and arylcarbamate derivatives with N-benzylpiperidine and N-benzylpiperazine moieties as cholinesterases inhibitors. Eur. J. Med. Chem. 45 (2010), 5602–5611.
220. Wiesner, J., Kriz, Z., Kuca, K., Jun, D., Koca, J., Influence of the acetylcholinesterase active site protonation on omega loop and active site dynamics. J. Biomol. Struct. Dyn. 28 (2010), 393–403.
221. Wilson, S.R., Zucker, P.A., Huang, R.R.C., Spector, A., Development of synthetic compounds with glutathione peroxidase activity. J. Am. Chem. Soc. 111 (1989), 5936–5939.
222. Wlodek, S.T., Clark, T.W., Scott, L.R., McCammon, J.A., Molecular dynamics of acetylcholinesterase dimer complexed with tacrine. J. Am. Chem. Soc. 119 (1997), 9513–9522.
223. Wu, M.Y., Esteban, G., Brogi, S., Shionoya, M., Wang, L., Campiani, G., Unzeta, M., Inokuchi, T., Butini, S., Marco-Contelles, J., Donepezil-like multifunctional agents: design, synthesis, molecular modeling and biological evaluation. Eur. J. Med. Chem., 2015, 10.1016/j.ejmech.2015.10.001.
224. Xie, L., Zheng, W., Xin, N., Xie, J.W., Wang, T., Wang, Z.Y., Ebselen inhibits iron-induced tau phosphorylation by attenuating DMT1 up-regulation and cellular iron uptake. Neurochem. Int. 61 (2012), 334–340.
225. Xie, S.S., Lan, J.S., Wang, X.B., Jiang, N., Dong, G., Li, Z.R., Wang, K.D., Guo, P.P., Kong, L.Y., Multifunctional tacrine-trolox hybrids for the treatment of Alzheimer's disease with cholinergic, antioxidant, neuroprotective and hepatoprotective properties. Eur. J. Med. Chem. 93 (2015), 42–50.
226. Xie, S.S., Wang, X.B., Li, J.Y., Yang, L., Kong, L.Y., Design, synthesis and evaluation of novel tacrine-coumarin hybrids as multifunctional cholinesterase inhibitors against Alzheimer's disease. Eur. J. Med. Chem. 64 (2013), 540–553.
227. Xu, Y., Colletier, J.P., Weik, M., Jiang, H., Moult, J., Silman, I., Sussman, J.L., Flexibility of aromatic residues in the active-site gorge of acetylcholinesterase: X-ray versus molecular dynamics. Biophys. J. 95 (2008), 2500–2511.
228. Zampieri, D., Grazia Mamolo, M., Laurini, E., Zanette, C., Florio, C., Collina, S., Rossi, D., Azzolina, O., Vio, L., Substituted benzo[d]oxazol-2(3H)-one derivatives with preference for the sigma1 binding site. Eur. J. Med. Chem. 44 (2009), 124–130.
229. Zampieri, D., Laurini, E., Vio, L., Golob, S., Fermeglia, M., Pricl, S., Mamolo, M.G., Synthesis and receptor binding studies of some new arylcarboxamide derivatives as sigma-1 ligands. Bioorg. Med. Chem. Lett. 24 (2014), 1021–1025.
230. Zampieri, D., Mamolo, M.G., Laurini, E., Florio, C., Zanette, C., Fermeglia, M., Posocco, P., Paneni, M.S., Pricl, S., Vio, L., Synthesis, biological evaluation, and three-dimensional in silico pharmacophore model for sigma(1) receptor ligands based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives. J. Med. Chem. 52 (2009), 5380–5393.
231. Zhang, L., Fourches, D., Sedykh, A., Zhu, H., Golbraikh, A., Ekins, S., Clark, J., Connelly, M.C., Sigal, M., Hodges, D., Guiguemde, A., Guy, R.K., Tropsha, A., Discovery of novel antimalarial compounds enabled by QSAR-based virtual screening. J. Chem. Inf. Model. 53 (2013), 475–492.
232. Zhang, W.T., Ruan, J.L., Wu, P.F., Jiang, F.C., Zhang, L.N., Fang, W., Chen, X.L., Wang, Y., Cao, B.S., Chen, G.Y., Zhu, Y.J., Gu, J., Chen, J.G., Design, synthesis, and cytoprotective effect of 2-aminothiazole analogues as potent poly(ADP-ribose) polymerase-1 inhibitors. J. Med. Chem. 52 (2009), 718–725.
233. Zhang, Y., Kua, J., McCammon, J.A., Role of the catalytic triad and oxyanion hole in acetylcholinesterase catalysis: an ab initio QM/MM study. J. Am. Chem. Soc. 124 (2002), 10572–10577.
234. Zheng, H., Youdim, M.B., Fridkin, M., Site-activated multifunctional chelator with acetylcholinesterase and neuroprotective–neurorestorative moieties for Alzheimer's therapy. J. Med. Chem. 52 (2009), 4095–4098.
235. Zhu, X., Raina, A.K., Perry, G., Smith, M.A., Alzheimer's disease: the two-hit hypothesis. Lancet Neurol. 3 (2004), 219–226.
236. Zhu, Y., Xiao, K., Ma, L., Xiong, B., Fu, Y., Yu, H., Wang, W., Wang, X., Hu, D., Peng, H., Li, J., Gong, Q., Chai, Q., Tang, X., Zhang, H., Shen, J., Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and beta-secretase. Bioorg. Med. Chem. 17 (2009), 1600–1613.
237. Zou, Y., Xu, L., Chen, W., Zhu, Y., Chen, T., Fu, Y., Li, L., Ma, L., Xiong, B., Wang, X., Li, J., He, J., Zhang, H., Xu, Y., Shen, J., Discovery of pyrazole as C-terminus of selective BACE1 inhibitors. Eur. J. Med. Chem. 68 (2013), 270–283.